Tudor Investment Corp ET AL Takes $6.06 Million Position in LeMaitre Vascular, Inc. $LMAT

Tudor Investment Corp ET AL purchased a new position in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) in the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 69,202 shares of the medical instruments supplier’s stock, valued at approximately $6,056,000.

Other hedge funds have also added to or reduced their stakes in the company. Royal Bank of Canada lifted its stake in LeMaitre Vascular by 1.5% during the first quarter. Royal Bank of Canada now owns 114,176 shares of the medical instruments supplier’s stock worth $9,579,000 after purchasing an additional 1,735 shares during the last quarter. AQR Capital Management LLC boosted its holdings in shares of LeMaitre Vascular by 36.4% during the 1st quarter. AQR Capital Management LLC now owns 27,878 shares of the medical instruments supplier’s stock valued at $2,339,000 after acquiring an additional 7,445 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in shares of LeMaitre Vascular by 4.7% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 12,078 shares of the medical instruments supplier’s stock worth $1,013,000 after purchasing an additional 539 shares during the last quarter. Millennium Management LLC boosted its position in LeMaitre Vascular by 119.8% during the 1st quarter. Millennium Management LLC now owns 211,222 shares of the medical instruments supplier’s stock worth $17,722,000 after buying an additional 115,141 shares during the period. Finally, Goldman Sachs Group Inc. raised its stake in shares of LeMaitre Vascular by 27.0% during the first quarter. Goldman Sachs Group Inc. now owns 262,445 shares of the medical instruments supplier’s stock valued at $22,019,000 after acquiring an additional 55,804 shares during the last quarter. 84.64% of the stock is owned by institutional investors.

Insider Activity

In other LeMaitre Vascular news, insider Trent G. Kamke sold 1,044 shares of the stock in a transaction that occurred on Friday, February 27th. The stock was sold at an average price of $110.29, for a total value of $115,142.76. Following the transaction, the insider owned 6,677 shares in the company, valued at approximately $736,406.33. This represents a 13.52% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director David B. Roberts sold 8,464 shares of the firm’s stock in a transaction that occurred on Friday, February 27th. The shares were sold at an average price of $106.80, for a total value of $903,955.20. Following the completion of the sale, the director directly owned 17,979 shares of the company’s stock, valued at $1,920,157.20. This trade represents a 32.01% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 215,438 shares of company stock worth $23,062,911 in the last three months. Company insiders own 9.50% of the company’s stock.

LeMaitre Vascular Stock Performance

Shares of LMAT stock opened at $109.99 on Wednesday. The firm has a 50 day moving average of $95.58 and a 200-day moving average of $89.79. The company has a market cap of $2.51 billion, a price-to-earnings ratio of 43.82, a price-to-earnings-growth ratio of 3.11 and a beta of 0.66. The company has a quick ratio of 10.95, a current ratio of 12.89 and a debt-to-equity ratio of 0.43. LeMaitre Vascular, Inc. has a 52 week low of $71.42 and a 52 week high of $115.33.

LeMaitre Vascular (NASDAQ:LMAT) last released its earnings results on Wednesday, February 25th. The medical instruments supplier reported $0.68 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.67 by $0.01. The company had revenue of $64.45 million for the quarter, compared to the consensus estimate of $62.98 million. LeMaitre Vascular had a net margin of 23.13% and a return on equity of 14.72%. LeMaitre Vascular’s quarterly revenue was up 15.7% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.49 EPS. LeMaitre Vascular has set its FY 2026 guidance at 2.810-3.010 EPS and its Q1 2026 guidance at 0.640-0.690 EPS. On average, equities analysts forecast that LeMaitre Vascular, Inc. will post 1.94 earnings per share for the current year.

LeMaitre Vascular Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, March 26th. Stockholders of record on Thursday, March 12th will be paid a $0.25 dividend. The ex-dividend date is Thursday, March 12th. This represents a $1.00 annualized dividend and a dividend yield of 0.9%. This is a boost from LeMaitre Vascular’s previous quarterly dividend of $0.20. LeMaitre Vascular’s dividend payout ratio (DPR) is 39.84%.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on the stock. Citizens Jmp boosted their price objective on shares of LeMaitre Vascular from $113.00 to $118.00 and gave the stock a “market outperform” rating in a research note on Thursday, February 26th. Wells Fargo & Company raised their price objective on LeMaitre Vascular from $87.00 to $94.00 and gave the stock an “equal weight” rating in a research report on Thursday, February 26th. Weiss Ratings raised shares of LeMaitre Vascular from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Tuesday, March 10th. Roth Mkm restated a “buy” rating and issued a $117.00 price target (up from $108.00) on shares of LeMaitre Vascular in a research report on Thursday, February 26th. Finally, Barrington Research increased their price objective on shares of LeMaitre Vascular from $95.00 to $105.00 and gave the stock an “outperform” rating in a research report on Thursday, February 26th. Four equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $105.80.

LeMaitre Vascular Profile

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company’s offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre’s product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.